DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Stifel Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $25

Stifel maintains Galmed Pharmaceuticals (NASDAQ:GLMD) with a Buy and lowers the price target from $35 to $25.

Benzinga · 03/13/2020 13:53

Stifel maintains Galmed Pharmaceuticals (NASDAQ:GLMD) with a Buy and lowers the price target from $35 to $25.